167 related articles for article (PubMed ID: 35307743)
21. Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition.
Graziani V; Garcia AR; Alcolado LS; Le Guennec A; Henriksson MA; Conte MR
Sci Rep; 2023 Jan; 13(1):1273. PubMed ID: 36690651
[TBL] [Abstract][Full Text] [Related]
22. N-myc-Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma.
Kuzuoglu-Ozturk D; Aksoy O; Schmidt C; Lea R; Larson JD; Phelps RRL; Nasholm N; Holt M; Contreras A; Huang M; Wong-Michalak S; Shao H; Wechsler-Reya R; Phillips JJ; Gestwicki JE; Ruggero D; Weiss WA
Cancer Res; 2023 Jan; 83(1):130-140. PubMed ID: 36264168
[TBL] [Abstract][Full Text] [Related]
23. An animal model of MYC-driven medulloblastoma.
Pei Y; Moore CE; Wang J; Tewari AK; Eroshkin A; Cho YJ; Witt H; Korshunov A; Read TA; Sun JL; Schmitt EM; Miller CR; Buckley AF; McLendon RE; Westbrook TF; Northcott PA; Taylor MD; Pfister SM; Febbo PG; Wechsler-Reya RJ
Cancer Cell; 2012 Feb; 21(2):155-67. PubMed ID: 22340590
[TBL] [Abstract][Full Text] [Related]
24. Spectrum of medulloblastoma subtypes and frequency of MYC amplification; Experience from a tertiary care center in Saudi Arabia.
Alassiri AH; Alsufiani FM; Almutairi AA; Almohini IA; Aldosari MA; Essa MF
Neurosciences (Riyadh); 2020 Jul; 25(3):218-221. PubMed ID: 32683405
[TBL] [Abstract][Full Text] [Related]
25. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
[TBL] [Abstract][Full Text] [Related]
26. α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth.
Sengupta S; Weeraratne SD; Sun H; Phallen J; Rallapalli SK; Teider N; Kosaras B; Amani V; Pierre-Francois J; Tang Y; Nguyen B; Yu F; Schubert S; Balansay B; Mathios D; Lechpammer M; Archer TC; Tran P; Reimer RJ; Cook JM; Lim M; Jensen FE; Pomeroy SL; Cho YJ
Acta Neuropathol; 2014 Apr; 127(4):593-603. PubMed ID: 24196163
[TBL] [Abstract][Full Text] [Related]
27. Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability.
Luo Z; Xin D; Liao Y; Berry K; Ogurek S; Zhang F; Zhang L; Zhao C; Rao R; Dong X; Li H; Yu J; Lin Y; Huang G; Xu L; Xin M; Nishinakamura R; Yu J; Kool M; Pfister SM; Roussel MF; Zhou W; Weiss WA; Andreassen P; Lu QR
Nat Commun; 2023 Feb; 14(1):762. PubMed ID: 36765089
[TBL] [Abstract][Full Text] [Related]
28. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
29. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
30. A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.
Wang F; Remke M; Bhat K; Wong ET; Zhou S; Ramaswamy V; Dubuc A; Fonkem E; Salem S; Zhang H; Hsieh TC; O'Rourke ST; Wu L; Li DW; Hawkins C; Kohane IS; Wu JM; Wu M; Taylor MD; Wu E
Oncotarget; 2015 Feb; 6(5):2709-24. PubMed ID: 25576913
[TBL] [Abstract][Full Text] [Related]
31. Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma.
Zitterbart K; Filkova H; Tomasikova L; Necesalova E; Zambo I; Kantorova D; Slamova I; Vranova V; Zezulkova D; Pesakova M; Pavelka Z; Veselska R; Kuglik P; Sterba J
J Neurooncol; 2011 Mar; 102(1):25-33. PubMed ID: 20607354
[TBL] [Abstract][Full Text] [Related]
32. ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors.
Mainwaring OJ; Weishaupt H; Zhao M; Rosén G; Borgenvik A; Breinschmid L; Verbaan AD; Richardson S; Thompson D; Clifford SC; Hill RM; Annusver K; Sundström A; Holmberg KO; Kasper M; Hutter S; Swartling FJ
Nat Commun; 2023 Mar; 14(1):1221. PubMed ID: 36869047
[TBL] [Abstract][Full Text] [Related]
33. The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity.
Vo BT; Wolf E; Kawauchi D; Gebhardt A; Rehg JE; Finkelstein D; Walz S; Murphy BL; Youn YH; Han YG; Eilers M; Roussel MF
Cancer Cell; 2016 Jan; 29(1):5-16. PubMed ID: 26766587
[TBL] [Abstract][Full Text] [Related]
34. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
[TBL] [Abstract][Full Text] [Related]
35. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
36. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
[TBL] [Abstract][Full Text] [Related]
37. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
39. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.
Weeraratne SD; Amani V; Teider N; Pierre-Francois J; Winter D; Kye MJ; Sengupta S; Archer T; Remke M; Bai AH; Warren P; Pfister SM; Steen JA; Pomeroy SL; Cho YJ
Acta Neuropathol; 2012 Apr; 123(4):539-52. PubMed ID: 22402744
[TBL] [Abstract][Full Text] [Related]
40. OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
Xu Z; Murad N; Malawsky D; Tao R; Rivero-Hinojosa S; Holdhof D; Schüller U; Zhang P; Lazarski C; Rood BR; Packer R; Gershon T; Pei Y
Clin Cancer Res; 2022 Oct; 28(19):4278-4291. PubMed ID: 35736214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
